Sunshine Biopharma Inc SBFM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
Trading Information
- Previous Close Price
- $2.79
- Day Range
- $2.68–2.85
- 52-Week Range
- $2.53–464.00
- Bid/Ask
- $2.68 / $2.78
- Shares Outstanding
- 760,970.00
- Market Cap
- $2.06M
- Volume/Avg
- 545 / 298,123
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 50
Valuation
Metric | SBFM |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.01 |
Price/Sales | 0.00 |
Price/Cash Flow | — |
Price/Earnings
SBFM
Financial Strength
Metric | SBFM |
|---|---|
Quick Ratio | 3.16 |
Current Ratio | 5.46 |
Interest Coverage | — |
Quick Ratio
SBFM
Profitability
Metric | SBFM |
|---|---|
Return on Assets (Normalized) | −17.13% |
Return on Equity (Normalized) | −21.79% |
Return on Invested Capital (Normalized) | −21.77% |
Return on Assets
SBFM
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|qm$r#&NF | LOCK|DS>%> | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|$M<z%<!< | LOCK|xZh!R | $48B | |||
| Haleon PLC ADR HLN | LOCK|%t#pmVz | LOCK|@m | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|l>nj>fng | LOCK|Bz | $32B | |||
| Viatris Inc VTRS | LOCK|%@<?!fd | LOCK|<f^ | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|Pb | LOCK|#R | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|ClvFlF | LOCK|?g | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|lX%pSD | LOCK|kj | $6B | |||
| Perrigo Co PLC PRGO | LOCK|d#K^c% | LOCK|Ptg | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|<QD###W | LOCK|qhKq | $2B |
United States